tirzepatide gastroparesis case report GLP-1 Gastroparesis: Hidden Dangers Beyond C Does Tirzepatide Cause Gastroparesis? Safety

The peptide storage guide has specific recommendations for travel scenarios

It's a catastrophic point of failure that we see far too often

The Dual-Energy X-ray Absorptiometry (DXA) substudy data from the landmark clinical trials reveals exactly how much muscle tax each peptide extracts versus how much actual fat they burn

Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%